Current Report · Items 3.03, 5.03, 7.01, 9.01 · 8-K
Nexalin Technology, Inc.
NXLNASDAQEQUITYCurrent
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Item 3.03. Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K (the “Current Report”) is incorporated herein by reference.
Filed Aug 27, 2026Accepted Aug 27, 2026, 7:30 AM EDTCIK 1527352Accession 0001829126-26-009387
Company context
We are a medical device company engaged in the design and development of innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device — referred to as “Generation 1” or “Gen-1” — that utilizes bioelectronic medical technology to treat anxiety, insomnia and depression without the need for drugs or psychotherapy. Our original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (the “FDA”) as a Class II device.
Current securities
Historical securities (1)
Disclosure sections
Items 3.03, 5.03, 7.01, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 3.03Item 3.03 - Material Modification to Rights
Item 3.03. Material Modification to Rights of Security Holders.
To the extent required by Item 3.03 of Form 8-K,
the information contained in Item 5.03 of this Current Report on Form 8-K (the “Current Report”) is incorporated herein by
reference.
Item 5.03Item 5.03 - Amendments to Articles/Bylaws
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year.
On August 26, 2026, Nexalin Technology, Inc. (the
“Company”) filed a certificate of amendment to the Company’s Certificate of Incorporation (the “Amendment”)
with the Secretary of State of the State of Delaware to effectuate a 1-for-30 reverse stock split (the “Reverse Stock Split”)
of the outstanding shares of the Company’s common stock, par value $0.001 per share (“Common Stock”). The Company’s
stockholders previously approved future reverse stock splits and granted the board of directors the authority to determine the exact split
ratios and when to proceed with any such reverse stock splits.
The Reverse Stock Split will become effective
on August 28, 2026, at 5:00 p.m., Eastern Time (the “Effective Time”) and the Common Stock is expected to begin trading on
The Nasdaq Capital Market on a Reverse Stock Split-adjusted basis on August 31, 2026, at market open under the existing ticker symbol,
“NXL.” As of the Effective Time, every thirty shares of the Company’s issued and outstanding Common Stock will be combined
into one share of Common Stock.
The par value and other terms of the Common Stock
will not be affected by the Reverse Stock Split. The Company’s post-Reverse Stock Split Common Stock CUSIP number will be 65345B300.
No fractional shares will be issued as a result
of the Reverse Stock Split. Stockholders of record who would otherwise be entitled to receive a fractional share of Common Stock will
receive a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied
by the closing price per share of the Common Stock (as adjusted for the Reverse Stock Split) on the Nasdaq Capital Market on August 28,
2026.
The foregoing description of the Amendment is
qualified in its entirety by reference to the Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report and is incorporated
herein by reference.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On August 27, 2026, the Company issued a press
release announcing the Reverse Stock Split. The press release is furnished as Exhibit 99.1 and incorporated by reference herein.
The information in this Item 7.01, including Exhibit
99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall
not be incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), whether
made before or after the date hereof, except as expressly set forth by specific reference in such filing. The furnishing of this information
will not be deemed an admission as to the materiality of any information contained therein.
Filed exhibits (1)
EX-99.1 (by filename) nexalintec_ex99-1.htmEX-99.1
3
nexalintec_ex99-1.htm
EXHIBIT 99.1
Exhibit 99.1
Nexalin Technology Announces Reverse Stock Split
HOUSTON - August 27, 2026 - Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), announces that its board of directors has approved a 1-for-30 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.
The reverse stock split will become effective on August 28, 2026, at 5:00 pm, Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) at market open under the existing ticker symbol, “NXL” on August 31, 2026, the date which has been approved by Nasdaq for the effectiveness of such split.
As of the Effective Time, every 30 shares of the Company’s issued and outstanding common stock will be combined into one share of common stock. The par value per share of the Company’s common stock will remain unchanged at $0.001.
The Co…
Open exhibit ↗